AFTER MONTH of uncertainty.

AFTER MONTH of uncertainty, process in law and delay, Erbitux (cetuximab), the investigational anticancer physic being developed by ImClone schemes Inc., Bristol-Myers Squibb Company (BMS) and Merck KGaA, is finally making real strides towards reaching the market. Merck freshly reported that independent reviewers have confirmed its internal assessment of the European colorectal trial data and provided an outline for filing for marketing approval in Europe

Merck says independent reviewers complet an analysis of radiologic data from its Phase II pivotal trial involving 330

...